<DOC>
	<DOCNO>NCT00447057</DOCNO>
	<brief_summary>This multicenter , randomize , Phase 2 , open label , parallel trial evaluate effect pemetrexed alone nonsquamous non-small cell lung cancer ( NSCLC ) second-line setting ( progression-free survival [ PFS ] , disease control rate , best response rate , time treatment failure [ TTTF ] , overall survival [ OS ] 1-year survival rate ) compare pemetrexed plus erlotinib combination .</brief_summary>
	<brief_title>Study Pemetrexed Versus Pemetrexed Plus Erlotinib Treatment Nonsquamous Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histological cytological diagnosis locally advance metastatic NSCLC nonsquamous histology amenable curative therapy . Failure previous treatment one prior platinumbased chemotherapy regimen . Good performance status . Adequate bone marrow reserve , renal hepatic function . Serious concomitant systemic disease . Inability take oral medication . Inability unwillingness take vitamin supplementation corticosteroid . Pregnancy / Breastfeeding . Treatment certain medicine prevent blood clotting .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>nonsquamous</keyword>
</DOC>